Who is IndicationIQ built for?

Pharma insight, patient engagement, and medical affairs teams — and the agencies delivering patient-support and launch-communications insight on their behalf.

How is this different from other social listening platforms?

Most tools lead with volume and sentiment. IndicationIQ turns public conversation into indication-specific unmet needs, misconceptions, and HCP signals — sized by frequency, linked to evidence, and structured for human-reviewed deliverables.

Can we use this for regulated client work?

Yes for insight workflows that need quote-level provenance, human approval, privacy controls, and structured exports. It does not replace your organisation’s medical, legal, privacy, or regulatory review.

IndicationIQ

Unmet needs, evidenced

IndicationIQ

Named patient insight, not just volume and sentiment

Ranked unmet needs and HCP signals from public conversation — by indication, every one backed by a verbatim quote.

Request a demo

Myeloma · Patient unmet needs · Review

Sample

Top finding

34%

Bone pain misread as disease progression

Misconception · 41 quotes

Supporting quote

“I didn't realise the bone pain was the myeloma — I thought the treatment wasn't working.”
Patient · Reddit

Product output — one named finding with source evidence

The difference

Generic listening vs one supported finding

Generic listening tool

Volume · sentiment · keywords

Volume this quarter12,847 mentions

Overall sentiment 71% negative

painfatiguefeartreatmentside effects

True — but nothing here tells you what to build or where the evidence is.

IndicationIQ

Named unmet needs, evidenced

IndicationIQ — one supported finding

Bone pain misread as disease progression

Misconception

“I didn't realise the bone pain was the myeloma — I thought the treatment wasn't working.”
Patient · Reddit r/multiplemyeloma

What you get

From lived experience to a defendable recommendation

Patient support · HCP launch

Understand lived experience

Journey-stage context, patient vs caregiver voice, and patient-language unmet needs — plus public HCP signals for the same indication.

Quote-level provenance

Inspect the evidence

Every finding links to source, date, and verbatim text. Open the quote trail before anything leaves the workspace.

Client-ready deliverables

Deliver the recommendation

Human review before export. Ranked insights and anonymised quotes structured for medical and compliance reviewers.

How it works

Four steps to client-ready evidence

Configure

Indication, keywords, sources, and project phase.

Collect

Public conversation from open sources you configure.

Extract

Named unmet needs sized by frequency, with context.

Review & export

Validate against verbatims, then ship report-ready evidence.

Pharma intelligence platform step by step — the same loop, written out for insight and medical comms teams.

Inside the workspace

Findings, evidence, and review in one place

Switch tabs to move from the recommendation to the unmet-need ranking and the quote library behind it.

app.indicationiq.com/dashboard

Sample data

Plaque psoriasis biologic support — H1 2026

Patient & caregiver insightsReview

Moderate-to-severe plaque psoriasis · 1,184 evidence items

The answer

Injection fear dominates first-dose conversation — but patients who misunderstand early flares are the ones most likely to quit before the biologic has a fair trial.

What matters most

1
Injection fear before first biologic dose
78% of corpus · 52 posts
Support materials need normalised injection-site imagery and nurse-led walkthroughs before day one.
2
Flare mistaken for treatment failure
71% of corpus · high-risk misconception
Week-three worsening is driving discontinuation — expectation-setting belongs in initiation, not the FAQ.
3
Prior authorization delay stress
58% of corpus · access burden
Coverage friction is an emotional load as much as a logistics problem — bridge programmes should be visible early.

Interactive preview — scroll inside the screen, switch tabs

Built for regulated review

Practices you can verify in the product

Public-source scope

Open platforms only — Reddit, X, Bluesky, forums, and similar.

Human review

Automation proposes; reviewers approve before client delivery.

Provenance

Source, date, and verbatim attached to every surfaced insight.

Privacy controls

Anonymised exports by default, erasure, and retention lifecycle.

See it on your indication

Walk through patient support or HCP launch insight with your therapy area.

Request a demo

FAQ

Common questions

Who is IndicationIQ built for?: Pharma insight, patient engagement, and medical affairs teams — and the agencies delivering patient-support and launch-communications insight on their behalf.
How is this different from other social listening platforms?: Most tools lead with volume and sentiment. IndicationIQ turns public conversation into indication-specific unmet needs, misconceptions, and HCP signals — sized by frequency, linked to evidence, and structured for human-reviewed deliverables.
Can we use this for regulated client work?: Yes for insight workflows that need quote-level provenance, human approval, privacy controls, and structured exports. It does not replace your organisation’s medical, legal, privacy, or regulatory review.